Mission
BioMetrx™ is a drug discovery and development company dedicated to significantly improving the clinical outcomes for advanced prostate, colorectal, and breast cancer patients.
read more
read more
Solutions
Rasstore™ is designed to extend the lives of advanced prostate cancer patients by transforming cancer’s death sentence into a disease state that can be managed by the patient’s own tumor control system.
read more
read more
Experts
BioMetrx’s founders have assembled a stellar team of experts and seasoned professionals in the field of science, medicine, and business to lead BioMetrx into the future...
read more
read more
Rasstore™ | The Science of Innovation
Rasstore™ works by restoring RASSF1A activity, which normally controls cell growth, but is decreased in cancer cells due primarily to methylation. RASSF1A is probably the most frequently methylated gene and is described as -methylated in at least 37 tumor types.
Rasstore™ can be used as a therapeutic and as a diagnostic. It is designed and scientifically synthesized to be a more effective therapeutic than the naturally occurring compound Mahanine (derived from curry plants). The bioengineered fluorescing portion of Rasstore™ also allows it to be used as a diagnostic tool to locate areas in the body that have concentrated amounts of the therapeutic inside of tumor cells.
read more| BioMetrx News | |
|---|---|
| Articles can be downloaded via lower left of each imbedded PDF. | |
| 22 March 2012 | Washington, D.C. Leads Nation in Prostate Cancer |
| 24 Jan 2012 | Georgetown University Medical Center Licenses “Theranostic” for Development |
| 18 Jan 2012 | BioMetrx Overview |
| 25 Feb 2010 | Journal of Medicinal Chemistry, 2010, Vol. 53, No. 6 |
| Spring 2007 | Milton Brown And Drug Discovery; GUMC’S Bold New Move in Therapeutic Research |





